脾切除对丙型病毒性肝炎后肝硬化门静脉高压症患者细胞免疫功能的影响

doi:10.3877/cma.j.issn.2095-3232.2015.04.010

中华肝脏外科手术学电子杂志 ›› 2015, Vol. 04 ›› Issue (04) : 232 -236. doi: 10.3877/cma.j.issn.2095-3232.2015.04.010

所属专题：文献；

临床研究

脾切除对丙型病毒性肝炎后肝硬化门静脉高压症患者细胞免疫功能的影响

纪泛扑¹, 黄娜², 张澍³, 蔡芝芳⁴, 蒋安⁵, 周蕊⁵, 李宝华², 任松⁵, 李宗芳³^,^†(

)

^1. 710004　西安交通大学第二附属医院干部病房普通外科；710004　西安交通大学第二附属医院感染科
^2. 710004　西安交通大学第二附属医院生物诊断治疗国家地方联合工程研究中心
^3. 710004　西安交通大学第二附属医院干部病房普通外科；710004　西安交通大学第二附属医院生物诊断治疗国家地方联合工程研究中心
^4. 710004　西安交通大学第二附属医院感染科
^5. 710004　西安交通大学第二附属医院干部病房普通外科

收稿日期:2015-05-12 出版日期:2015-08-10
通信作者: 李宗芳
基金资助:
国家自然科学基金青年项目(81300322，30901268); 国家自然科学基金重大研究计划项目(91442122)

Effect of splenectomy on cellular immune function of patients with hepatitis C virus related cirrhotic portal hypertension

Fanpu Ji¹, Na Huang², Shu Zhang³, Zhifang Cai⁴, An Jiang⁵, Rui Zhou⁵, Baohua Li², Song Ren⁵, Zongfang Li³^,^†()

^1. Department of General Surgery, the Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China; Department of Infectious Disease, the Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China
^2. Biological Diagnosis and Treatment of National and Local Joint Engineering Research Center, the Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China
^3. Department of General Surgery, the Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China ; Biological Diagnosis and Treatment of National and Local Joint Engineering Research Center, the Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China
^4. Department of Infectious Disease, the Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China
^5. Department of General Surgery, the Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China

Received:2015-05-12 Published:2015-08-10
Corresponding author: Zongfang Li
About author:
Corresponding author: Li Zongfang, Email:lzf2568@gmail.com

全文 ( ) 下载PDF ( ) 导出引用

引用本文：

纪泛扑, 黄娜, 张澍, 蔡芝芳, 蒋安, 周蕊, 李宝华, 任松, 李宗芳. 脾切除对丙型病毒性肝炎后肝硬化门静脉高压症患者细胞免疫功能的影响[J]. 中华肝脏外科手术学电子杂志, 2015, 04(04): 232-236.

Fanpu Ji, Na Huang, Shu Zhang, Zhifang Cai, An Jiang, Rui Zhou, Baohua Li, Song Ren, Zongfang Li. Effect of splenectomy on cellular immune function of patients with hepatitis C virus related cirrhotic portal hypertension[J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2015, 04(04): 232-236.

目的

探讨脾切除对丙型病毒性肝炎（丙肝）后肝硬化门静脉高压症患者细胞免疫功能的影响。

方法

本前瞻性研究对象为2011年12月至2013年12月在西安交通大学第二附属医院行脾切除+贲门周围血管离断术的12例丙肝后肝硬化门静脉高压症患者。其中男4例，女8例；平均年龄（55±8）岁。另选择12名健康体检者作为对照组。所有入选者均签署知情同意书，符合医学伦理学规定。观察患者术前及术后2、6周外周血NK、自然杀伤T细胞（NKT）、CD4⁺、CD8⁺ T细胞百分率及CD4⁺/CD8⁺比值的变化。手术前后不同淋巴细胞亚群的比较采用Wilcoxon秩和检验。

结果

患者术后6周CD3^-CD56⁺CD16⁺ NK细胞百分率7.7%，明显高于术前的6.2%（T=1.992，P<0.05）；术后2、6周CD56^dim NK细胞百分率分别为94.9%、96.4%，明显高于术前的87.9% （T=2.747，2.201；P<0.05）；术后2、6周CD56^bright NK细胞百分率分别为3.8%、2.4%，明显低于术前的9.2%（T=2.747，2.201；P<0.05）。术后2、6周CD3⁺CD56⁺ NKT细胞百分率分别为7.3%、7.0%，明显高于术前的6.5%（T=2.275，1.572；P<0.05）。术后2周CD4⁺ T细胞百分率为41.7%，明显低于术前的45.7%（T=3.059，P<0.05），术后6周进一步降低至26.7%（T=2.201，P<0.05）；而CD8⁺ T细胞百分率术后2周从术前的21.1%明显升高至24.8%（T=2.432，P<0.05），术后6周进一步升高至35.3%（T=1.992，P<0.05）。术前CD4⁺/CD8⁺比值为2.0，在术后2、6周明显下降至1.4、0.8（T=2.981，1.992；P<0.05）。

结论

丙肝后肝硬化门静脉高压症患者脾切除术后细胞免疫功能明显改善。

关键词: 肝硬化, 肝炎，丙型，慢性, 脾切除术, NK细胞, T淋巴细胞

Objective

To investigate the effect of splenectomy on cellular immune function of patients with hepatitis C virus (HCV) related cirrhotic portal hypertension.

Methods

Twelve patients with HCV-related cirrhotic portal hypertension undergoing splenectomy + pericardial devascularization in the Second Affiliated Hospital of Xi'an Jiaotong University between December 2011 and December 2013 were enrolled in this prospective study. Among the 12 patients, 4 were males and 8 were females with the average age of (55±8) years old. Moreover, 12 healthy people were enrolled in the control group. The informed consents of all patients were obtained and the local ethical committee approval had been received. Percentage of natural killer (NK) cell, natural killer T (NKT) cell, CD4⁺ cell, CD8⁺ T cell and CD4⁺/CD8⁺ ratio in peripheral blood before and 2, 6 weeks after splenectomy were observed. The comparison on different lymphocyte subsets was conducted using Wilcoxon rank-sum test.

Results

The percentage of CD3^-CD56⁺CD16⁺ NK cell 6 weeks after splenectomy was 7.7%, which was significantly higher than 6.2% before splenectomy (T=1.992, P<0.05). And the percentage of CD56^dim NK cell 2 and 6 weeks after splenectomy was respectively 94.9% and 96.4%, which was significantly higher than 87.9% before splenectomy (T=2.747, 2.201; P<0.05). The percentage of CD56^bright NK cell 2 and 6 weeks after splenectomy was respectively 3.8% and 2.4%, which was significantly lower than 9.2% before splenectomy (T=2.747, 2.201; P<0.05). The percentage of CD3⁺CD56⁺ NKT cell 2 and 6 weeks after splenectomy was respectively 7.3% and 7.0%, which was significantly higher than 6.5% before splenectomy (T=2.275, 1.572; P<0.05). Percentage of CD4⁺ T cell 2 weeks after splenectomy was 41.7%, which was significantly lower than 45.7% before splenectomy (T=3.059, P<0.05), and further decreased to 26.7% 6 weeks after splenectomy (T=2.201, P<0.05), while percentage of CD8⁺ T cell increased from 21.1% before splenectomy to 24.8% 2 weeks after splenectomy (T=2.432, P<0.05), and further increased to 35.3% 6 weeks after splenectomy (T=1.992, P<0.05). The CD4⁺/CD8⁺ ratio before splenectomy was 2.0 and decreased to 1.4 and 0.8 respectively 2 and 6 weeks after splenectomy (T=2.981, 1.992; P<0.05).

Conclusion

The cellular immune function of patients with HCV related cirrhotic portal hypertension after splenectomy improves significantly.

Key words: Liver cirrhotic, Hepatitis C, chronic, Splenectomy, NK cell, T lymphocytes

表1 两组术前及术后2、6周NK、NKT细胞的变化（%）

组别		例数	CD3^-CD56⁺CD16⁺ NK	CD56^dim NK	CD56^bright NK	CD3⁺CD56⁺ NKT
对照组		12	18.2(6.1～42.2)	95.8(84.6～98.6)	4.2(1.4～15.4)	4.2(1.1～13.8)
研究组		?	?	?	?	?
?	术前	12	6.2(2.6～18.7) ^a	87.9(74.4～98.7)^a	9.2(1.3～25.6)^a	6.5(3.2～12.8)
?	术后2周	12	6.9(3.1～24.5)	94.9(83.0～98.8)^b	3.8(1.2～17.0)^b	7.3(3.1～14.3)^b
?	术后6周	12	7.7(5.0～24.2)^b	96.4(90.6～98.3)^b	2.4(1.7～9.4)^b	7.0(5.4～16.4)

表1 两组术前及术后2、6周NK、NKT细胞的变化（%）

组别		例数	CD3^-CD56⁺CD16⁺ NK	CD56^dim NK	CD56^bright NK	CD3⁺CD56⁺ NKT
对照组		12	18.2(6.1～42.2)	95.8(84.6～98.6)	4.2(1.4～15.4)	4.2(1.1～13.8)
研究组		?	?	?	?	?
?	术前	12	6.2(2.6～18.7) ^a	87.9(74.4～98.7)^a	9.2(1.3～25.6)^a	6.5(3.2～12.8)
?	术后2周	12	6.9(3.1～24.5)	94.9(83.0～98.8)^b	3.8(1.2～17.0)^b	7.3(3.1～14.3)^b
?	术后6周	12	7.7(5.0～24.2)^b	96.4(90.6～98.3)^b	2.4(1.7～9.4)^b	7.0(5.4～16.4)

表2 两组术前及术后2、6周T细胞亚群的变化

组别		例数	CD4⁺ T（%）	CD8⁺ T（%）	CD4⁺/CD8⁺比值
对照组		12	36.1(28.3～59.7)	30.4(13.9～41.1)	1.2(0.9～2.2)
研究组		?	?	?	?
?	术前	12	45.7(38.4～63.7) ^a	21.1(16.6～35.6)^a	2.0(1.1～3.4)^a
?	术后2周	12	41.7(28.0～55.6) ^b	24.8(18.4～39.2)^b	1.4(0.8～3.0) ^b
?	术后6周	12	26.7(24.2～51.4) ^b	35.3(15.1～44.8) ^b	0.8(0.6～3.4) ^b

表2 两组术前及术后2、6周T细胞亚群的变化

组别		例数	CD4⁺ T（%）	CD8⁺ T（%）	CD4⁺/CD8⁺比值
对照组		12	36.1(28.3～59.7)	30.4(13.9～41.1)	1.2(0.9～2.2)
研究组		?	?	?	?
?	术前	12	45.7(38.4～63.7) ^a	21.1(16.6～35.6)^a	2.0(1.1～3.4)^a
?	术后2周	12	41.7(28.0～55.6) ^b	24.8(18.4～39.2)^b	1.4(0.8～3.0) ^b
?	术后6周	12	26.7(24.2～51.4) ^b	35.3(15.1～44.8) ^b	0.8(0.6～3.4) ^b

[1]	Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection[J]. Nat Rev Gastroenterol Hepatol, 2013, 10(9): 553-562.
[2]	Gower E, Estes C, Blach S, et al. Global epidemiology and genotype distribution of the hepatitis C virus infection[J]. J Hepatol, 2014,61 Suppl 1: S45-57.
[3]	张澍，李宗芳．脾脏功能与脾脏外科研究现状与展望[J]．中华实验外科杂志，2014, 31(2): 231-233.
[4]	Rosen HR. Emerging concepts in immunity to hepatitis C virus infection[J]. J Clin Invest, 2013, 123(10): 4121-4130.
[5]	Sugimoto K, Shiraki K. Different aspects of CD4 T cells that lead to viral clearance or persistence of HCV infection [J]. Hepatol Int, 2012, 6(1): 350-355.
[6]	Vivier E, Raulet DH, Moretta A, et al. Innate or adaptive immunity? the example of natural killer cells[J]. Science, 2011, 331(6013): 44-49.
[7]	Jost S, Altfeld M. Control of human viral infections by natural killer cells[J]. Annu Rev Immunol, 2013(31): 163-194.
[8]	Lunemann S, Schlaphoff V, Cornberg M, et al. NK cells in hepatitis C: role in disease susceptibility and therapy[J]. Dig Dis, 2012, 30 Suppl 1: 48-54.
[9]	De Maria A, Bozzano F, Cantoni C, et al. Revisiting human natural killer cell subset function revealed cytolytic CD56(dim)CD16⁺ NK cells as rapid producers of abundant IFN-gamma on activation[J]. Proc Natl Acad Sci U S A, 2011, 108(2): 728-732.
[10]	Schulze Zur Wiesch J, Ciuffreda D, Lewis-Ximenez L, et al. Broadly directed virus-specific CD4⁺ T cell responses are primed during acute hepatitis C infection, but rapidly disappear from human blood with viral persistence[J]. J Exp Med, 2012, 209(1): 61-75.
[11]	Hashimoto N, Shimoda S, Kawanaka H, et al. Modulation of CD4⁺ T cell responses following splenectomy in hepatitis C virus-related liver cirrhosis[J]. Clin Exp Immunol, 2011, 165(2): 243-250.
[12]	Nomura Y, Kage M, Ogata T, et al. Influence of splenectomy in patients with liver cirrhosis and hypersplenism[J]. Hepatol Res, 2014, 44(10): E100-109.
[13]	谢玉梅，李冰，马力，等．丙型肝炎肝硬化患者脾切除或脾栓塞术后抗病毒治疗的疗效观察[J]．中华肝脏病杂志, 2012, 20(2): 112-115.
[14]	Ji F, Zhang S, Huang N, et al. Splenectomy prior to antiviral therapy in patients with hepatitis C virus related decompensated cirrhosis [J]. Braz J Infect Dis, 2013, 17(5): 601-605.
[15]	Bozzano F, Picciotto A, Costa P, et al. Activating NK cell receptor expression/function (NKp30, NKp46, DNAM-1) during chronic viraemic HCV infection is associated with the outcome of combined treatment[J]. Eur J Immunol, 2011, 41(10): 2905-2914.
[16]	Oliviero B, Mele D, Degasperi E, et al. Natural killer cell dynamic profile is associated with treatment outcome in patients with chronic HCV infection[J]. J Hepatol, 2013, 59(1): 38-44.
[17]	Xiao YS, Gao Q, Xu XN, et al. Combination of intratumoral invariant natural killer T cells and interferon-gamma is associated with prognosis of hepatocellular carcinoma after curative resection[J]. PLoS One, 2013, 8(8): e70345.
[18]	Werner JM, Heller T, Gordon AM, et al. Innate immune responses in hepatitis C virus-exposed healthcare workers who do not develop acute infection[J]. Hepatology, 2013, 58(5): 1621-1631.

[1]	罗晨, 宗开灿, 李世颖, 傅应亚. 微小RNA-199a-3p调控CD4^＋T细胞表达参与肺炎支原体肺炎患儿免疫反应研究[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(05): 569-574.
[2]	李建美, 邓静娟, 杨倩. 两种术式联合治疗肝癌合并肝硬化门静脉高压的安全性及随访评价[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 41-44.
[3]	吴方园, 孙霞, 林昌锋, 张震生. HBV相关肝硬化合并急性上消化道出血的危险因素分析[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 45-47.
[4]	莫闲, 杨闯. 肝硬化患者并发门静脉血栓危险因素的Meta分析[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 678-683.
[5]	陈亚峰, 李江斌, 王栋, 臧莉, 鲁建国, 董瑞. 腹腔镜脾切除术在巨脾脾动脉栓塞后远期治疗中的应用[J]. 中华普外科手术学杂志(电子版), 2023, 17(05): 571-574.
[6]	张其坤, 商福超, 李琪, 栗光明, 王孟龙. 联合脾切除对肝癌合并门静脉高压症患者根治性切除术后的生存获益分析[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 613-618.
[7]	林文斌, 郑泽源, 郑文能, 郁毅刚. 外伤性脾破裂腹腔镜脾切除术患者中转开腹风险预测模型构建[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 619-623.
[8]	韩宇, 张武, 李安琪, 陈文颖, 谢斯栋. MRI肝脏影像报告和数据系统对非肝硬化乙肝患者肝细胞癌的诊断价值[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 669-673.
[9]	李翠平, 陈晓燕, 钱师宇, 林惠珠, 曾彩辉, 阳莉, 卢建溪. 不同抗凝剂保存液对脐血培养的NK细胞增殖及杀伤效应的影响[J]. 中华肝脏外科手术学电子杂志, 2023, 12(05): 572-576.
[10]	秦维, 王丹, 孙玉, 霍玉玲, 祝素平, 郑艳丽, 薛瑞. 血清层粘连蛋白、Ⅳ型胶原蛋白对代偿期肝硬化食管胃静脉曲张出血的预测价值[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 447-451.
[11]	张雯, 宋牡丹, 邓雪婷, 张云. 强化营养支持辅助奥曲肽治疗肝硬化合并食管胃底静脉曲张破裂出血的疗效及再出血危险因素[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 456-460.
[12]	朱翔宇, 王建美, 张辉, 叶红英. 无创左心室压力-应变循环技术在左心室功能参数与肝硬化的相关性分析[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 494-498.
[13]	杨琬芳, 许晶, 张耀方, 王青, 杨智超, 任方刚, 王宏伟. NK和NKT细胞对急性髓系白血病患者的临床影响[J]. 中华临床医师杂志(电子版), 2023, 17(9): 932-938.
[14]	孔凡彪, 杨建荣. 肝脏基础疾病与结直肠癌肝转移之间关系的研究进展[J]. 中华临床医师杂志(电子版), 2023, 17(07): 818-822.
[15]	符梅沙, 周玉华, 李慧, 薛春颜. 淋巴细胞免疫治疗对复发性流产患者外周血T淋巴细胞亚群分布与PD1/PD-L1表达的影响及意义[J]. 中华临床医师杂志(电子版), 2023, 17(06): 726-730.

阅读次数

全文

摘要

选择文件类型/文献管理软件名称

选择包含的内容

Effect of splenectomy on cellular immune function of patients with hepatitis C virus related cirrhotic portal hypertension

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

Effect of splenectomy on cellular immune function of patients with hepatitis C virus related cirrhotic portal hypertension